search
pharmaceutical companies
Trends
- 1Kobayashi Pharmaceutical weighs takeover offer above ¥500 billion●Kobayashi Pharmaceutical, the firm that was at the center of a supplement contamination scandal involving suspected deat
Kobayashi Pharmaceutical, the Japanese company at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer worth more than ¥500 billion. The news has drawn attention given the company's damaged reputation and the uncertain future of its consumer health business following the red yeast rice supplement scandal.
- 2European capital to help Colombian biotech firm produce 250 million vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines
A Colombian biotechnology company has received European investment to expand vaccine production, with plans to manufacture up to 250 million doses. The deal reflects Europe's push to strengthen global vaccine supply chains and Latin America's growing role in pharmaceutical manufacturing. Details on the investors and timelines have not yet been widely reported.
- 3
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 4Meta paid ads promote Israeli settlement homes in West Bank●Meta runs paid ads promoting luxury homes in illegal Israeli settlements in the occupied West Bank. The same platform th
Meta is running paid advertisements promoting luxury homes in Israeli settlements in the occupied West Bank, according to reports circulating online. Critics point out the contradiction: the platform bans ads for counterfeit goods and unauthorized pharmaceuticals, yet accepts money from Israeli real estate companies marketing properties on Palestinian land. Settlements are considered illegal under international law, and the ads are drawing accusations that Meta is profiting from their promotion.
- 5Biosimilars Sector Poised for M&A Shake-Up as Patent Cliff Looms●Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A
Legal and industry analysts say the biosimilars market has reached an inflection point, with regulatory reform, a maturing patent litigation framework and an approaching wave of major biologic patent expirations reshaping merger and acquisition strategy. Commentators expect pharmaceutical companies to pursue deals to capture market share as blockbuster biologics lose exclusivity and cheaper biosimilar competition intensifies.